Medable Secures $25M Venture Funding to Drive Global Adoption of Decentralized Clinical Trials

May 04, 2020•about 5 years ago

Amount Raised

$25 Million

Palo Alto

Description

Medable, Inc., the leading global platform for decentralized clinical trials, today announced $25 million in funding to accelerate clinical drug development with digital technology, enabling effective new therapies to reach patients faster. The investment will be used to extend product development, partnerships and market adoption for Medable’s decentralized trial platform, which brings together clinical trial participants, clinical research sites, partners and analytics to enable more patient-centric and informed clinical research.

Company Information

Company

Medable

Location

Palo Alto, California, United States

About

Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech